-
Pharmacovigilance during treatment of multiple sclerosis: Early recognition of CNS complications
Wijburg, M. T., Warnke, C., McGuigan, C., Koralnik, I. J., Barkhof, F., Killestein, J. & Wattjes, M. P., 1 Feb 2021, In: Journal of Neurology, Neurosurgery and Psychiatry. 92, 2, p. 177-188 12 p., 324534.Research output: Contribution to journal › Review article › Academic › peer-review
-
Application of “Mentzer’s PML case definition” to natalizumab-treated patients in the setting of strict MRI-based pharmacovigilance
Wijburg, M. T., Warnke, C., Killestein, J. & Wattjes, M. P., 1 Sept 2020, In: Journal of neurology. 267, 9, p. 2599-2602 4 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Serum neurofilaments as candidate biomarkers of natalizumab-associated PML
Loonstra, F. C., Verberk, I. M. W., Wijburg, M. T., Wattjes, M. P., Teunissen, C. E., van Oosten, B. W., Uitdehaag, B. M. J., Killestein, J. & van Kempen, Z. L. E., Sept 2019, In: MULTIPLE SCLEROSIS JOURNAL. 25, p. 284-284Research output: Contribution to journal › Meeting Abstract › Academic
- All publications
